Scanvio Medical: The Venture Leader Medtech harnessing AI for faster non-invasive endometriosis detection

19.08.2025 17:00, Rita Longobardi

Meet Stefan Tuchschmid, CEO of Scanvio. The Medtech startup builds AI software that makes standard ultrasounds expert tools for faster, non-invasive endometriosis detection. In late September, Stefan and the other nine Swiss National Medtech Team members will fly to Boston on a business development and investor roadshow.

Name: Stefan Tuchschmid
Location: Winterthur, Switzerland
Nationality: Swiss
Graduated from: ETH Zurich
Job title: CEO & Co-Founder
Number of employees: 11
Money raised: CHF 4.4M

Can you tell us who your product or solution helps, and how?
Scanvio helps gynecologists perform expert-level ultrasound exams by providing real-time AI guidance. Our first application focuses on endometriosis, a condition affecting over 10% of women, where diagnosis typically takes 8–12 years. By integrating directly with existing ultrasound machines, we enable earlier, faster, and more accurate diagnoses with no additional hardware!

What market are you addressing and what is the potential of your startup in that market?
We are addressing the USD 13B global ultrasound market, starting with the high-impact segment of women’s health. Our initial focus on endometriosis is just the beginning; our platform can scale to support other gynecological and general diagnostic applications. Long-term, we aim to become the category leader for AI-powered real-time ultrasound interpretation.

How and where did you come up with the idea for your startup?
The core team that later became Scanvio was already working on the concept. When I discovered the project at the ETH AI Center as Entrepreneur in Residence, I knew instantly it was what I had been looking for - an outstanding application of AI in MedTech with real clinical and business relevance. I joined to help shape it into a company.

What do you expect from the Venture Leaders roadshow, and how do you think it will help you achieve your vision?
We’re looking to build relationships with investors who understand both deep tech and MedTech. Exposure to the U.S. ecosystem will help us refine our strategy for FDA approval and international scaling. We also hope to connect with founders and mentors who’ve navigated similar paths.
What are your team’s key achievements to date?
We closed a USD 3.4M seed round backed by 40 angel investors, set up clinical pilots in top Swiss hospitals, and won a major Innosuisse grant with ETH Zurich and Kantonsspital Baden. Technically, we’ve achieved real-time AI inference on live ultrasound video, and went from concept to first-in-patient in only 8 months.

Is there a key principle or value that guides you as you build your company?
We operate with “transparency as default.” Unless there’s a clear reason for confidentiality, everyone has full access to all information. This enables better decision-making, empowers the team with context, and helps avoid unnecessary politics or second-guessing.

What is the most important lesson you have learned as a founder?
It’s not about the technology, not about the product, and only a little about abstract markets. Success comes from identifying real clinical needs, matching them with effective solutions, and building a compelling business case around them.

What is your favorite productivity hack or tool and why?
Truly committing to and living OKRs (Objective and Key Results) keeps us focused and aligned. In parallel, tools like Calendly or Notion help to streamline processes.

What was your dream job when you were a child?
After the typical fireman, astronaut, and soccer player phases, I wanted to become a doctor. While I didn’t follow that path directly, I came pretty close - and I truly enjoy working alongside clinicians daily to improve healthcare.